Likewise, in 2022, valoctocogene roxaparvovec (Roctavian), a gene therapy agent vector-built upon AAV5-hFVIII-SQ, secured EMA approval for treating severe hemophilia A (congenital factor VIII deficiency) in adults without a history of FVIII inhibitors and without detectable antibodies to AAV5 [25]. The gene discussed is F8; the disease is hemophilia A.